Physician profile
William Mclaughlin
NPI 1104870971
$8,409.98
in general payments reported to CMS, 2019-2025
37 companies · $249 in 2025
The $249 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $875 · 2020: $410 · 2021: $1,025 · 2022: $1,811 · 2023: $1,950 · 2024: $2,090 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,262 · Gift: $27.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,261.94 |
| Gift | $27.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,050.05 | 2019-2025 | |
| Janssen Biotech, INC. | $1,319.75 | 2019-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $802.43 | 2019-2024 | Trulance, Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $619.16 | 2019-2025 | Entyvio, Gattex |
| Ironwood Pharmaceuticals, INC | $415.34 | 2019-2025 | Linzess |
| Celgene Corporation | $397.23 | 2021-2024 | Zeposia |
| Genzyme Corporation | $366.20 | 2022-2024 | |
| Pfizer INC. | $270.96 | 2019-2025 | |
| Olympus America INC. | $262.52 | 2021-2023 | Evis Exera Lll Colonovideoscope |
| Merck Sharp & Dohme LLC | $216.94 | 2021-2024 | Dificid |
| Gilead Sciences, INC. | $173.02 | 2019-2024 | |
| Ardelyx, INC. | $154.31 | 2022-2024 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $145.78 | 2022-2024 | Dupixent |
| Braintree Laboratories, INC. | $140.30 | 2022-2025 | Suflave, Sutab |
| Janssen Scientific Affairs, LLC | $122.55 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $116.85 | 2023-2024 | Omvoh |
| Nestle Healthcare Nutrition INC. | $115.69 | 2021-2023 | |
| Qol Medical, LLC | $101.91 | 2021-2023 | Sucraid |
| Phathom Pharmaceuticals, INC. | $95.23 | 2024 | Voquezna |
| Aimmune Therapeutics, INC. | $79.87 | 2024-2025 | Zenpep |
| Boston Scientific Corporation | $63.62 | 2022 | |
| Madrigal Pharmaceuticals | $55.06 | 2024-2025 | Resmetirom, Rezdiffra |
| Redhill Biopharma INC. | $52.91 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $43.68 | 2019-2022 | |
| Allergan, INC. | $33.37 | 2020 | |
| Ferring Pharmaceuticals INC. | $28.76 | 2021-2023 | Cimzia |
| Amgen INC. | $27.75 | 2020-2022 | |
| Evoke Pharma, INC. | $25.36 | 2022 | |
| Romark Laboratories, Lc | $20.49 | 2019-2020 | |
| Intra-Sana Laboratories | $19.04 | 2021 | |
| Medtronic, INC. | $18.95 | 2021 | |
| Ucb, INC. | $14.59 | 2019 | |
| Daiichi Sankyo INC. | $14.50 | 2019 | |
| Fresenius Kabi USA, LLC | $14.19 | 2024 | Idacio |
| Alfasigma USA, INC. | $11.62 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.